The expression of matrix metalloproteinase matrilysin indicates the degree of inflammation in ulcerative colitis

被引:84
作者
Matsuno, K [1 ]
Adachi, Y [1 ]
Yamamoto, H [1 ]
Goto, A [1 ]
Arimura, Y [1 ]
Endo, T [1 ]
Itoh, F [1 ]
Imai, K [1 ]
机构
[1] Sapporo Med Univ, Dept Internal Med 1, Chuo Ku, Sapporo, Hokkaido 0608543, Japan
关键词
immunohistochemistry; matrix metalloproteinase; matrilysin; severity of inflammation; ulcerative colitis;
D O I
10.1007/s005350300062
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background. Any alteration in the synthesis and breakdown of the extracellular matrix is important in tissue remodeling during inflammation and wound healing. The degradation of the extracellular matrix components is regulated by a cascade of matrix metalloproteinases (MMPs). The present study attempted to assess the relationship between MMPs and the degree of inflammation in ulcerative colitis. Methods. The expression of MMPs, including MMP-1, -2, -3, -7 (matrilysin), and -9, and that of their inhibitors (tissue inhibitor of metalloproteinases [TIMP]-1 and -2) were analyzed immunohistochemically by using 52 formalin-fixed and paraffin-embedded specimens from patients with ulcerative colitis who had undergone a biopsy or surgery. Results. It was observed that MMP-1, -2, and -9, and the TIMPs were expressed in stromal cells, MMP-3 was expressed in both the epithelial cells and stromal components, and matrilysin was expressed only in the epithelial cells on the edge of ulcers. The expression of the MMPs was increased compared with that of the TIMPs. The frequency of matrilysin expression was increased corresponding to the severity of the inflammation. Matrilysin was also expressed in epithelial cells with dysplasia and cancer. Conclusions. Matrilysin expression could be an important marker of activity and could be used for the prediction of subsequent transformation in patients with ulcerative colitis.
引用
收藏
页码:348 / 354
页数:7
相关论文
共 37 条
[1]  
Adachi Y, 2001, INT J CANCER, V95, P290, DOI 10.1002/1097-0215(20010920)95:5<290::AID-IJC1050>3.0.CO
[2]  
2-I
[3]  
Adachi Y, 1998, INT J ONCOL, V13, P1031
[4]   Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers [J].
Adachi, Y ;
Yamamoto, H ;
Itoh, F ;
Hinoda, Y ;
Okada, Y ;
Imai, K .
GUT, 1999, 45 (02) :252-258
[5]  
BARAGI VM, 1994, J BIOL CHEM, V269, P12692
[6]   Matrix metalloproteinase levels are elevated in inflammatory bowel disease [J].
Baugh, MD ;
Perry, MJ ;
Hollander, AP ;
Davies, DR ;
Cross, SS ;
Lobo, AJ ;
Taylor, CJ ;
Evans, GS .
GASTROENTEROLOGY, 1999, 117 (04) :814-822
[7]   MATRIX METALLOPROTEINASES - A REVIEW [J].
BIRKEDALHANSEN, H ;
MOORE, WGI ;
BODDEN, MK ;
WINDSOR, LJ ;
BIRKEDALHANSEN, B ;
DECARLO, A ;
ENGLER, JA .
CRITICAL REVIEWS IN ORAL BIOLOGY & MEDICINE, 1993, 4 (02) :197-250
[8]   ROLE OF COLLAGENASE IN COLONIC ANASTOMOSES - A REAPPRAISAL [J].
CHOWCAT, NL ;
SAVAGE, FJ ;
HEMBRY, RM ;
BOULOS, PB .
BRITISH JOURNAL OF SURGERY, 1988, 75 (04) :330-334
[9]   Beneficial effects of Batimastat (BB-94), a matrix metalloproteinase inhibitor, in rat experimental colitis [J].
Di Sebastiano, P ;
di Mola, FF ;
Artese, L ;
Rossi, C ;
Mascetta, G ;
Pernthaler, H ;
Innocenti, P .
DIGESTION, 2001, 63 (04) :234-239
[10]   Ulcerative colitis [J].
Farrell, RJ ;
Peppercorn, MA .
LANCET, 2002, 359 (9303) :331-340